| Patient | Eva Perón |
|---|---|
| Date of birth | 1919-05-07 |
| Identifiers | MRN HR-ML025-SYN-TD; SSN (made up) 000-25-7316 |
| Document date | 1951-05-18 |
| Author | Lucía Barragán, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review two weeks after completing chemoradiation and brachytherapy. [S]
Ms. Perón returns two weeks after her last brachytherapy treatment. She completed 25 fractions of pelvic radiation and five weekly cisplatin doses without a break, then four brachytherapy treatments, finishing eight weeks after the start. The bladder infection in the third week cleared with nitrofurantoin. The diarrhea settled once radiation ended and she has not needed loperamide for two weeks; nausea stopped after the last cisplatin. She has no bleeding, only a light discharge. For the past ten days she has had about eight hot flashes a day, night sweats that wake her, and vaginal dryness. She has no ringing in the ears or numbness in her hands or feet. She is very tired but walks daily and is working mornings. She has kept seeing the social worker. [S]
| Element | Detail |
|---|---|
| Treatment | 45 Gy in 25 fractions with five weekly cisplatin doses, then four brachytherapy fractions, in eight weeks |
| Side effects | Diarrhea resolved; nausea gone; no ringing or numbness; tired |
| New symptoms | Hot flashes about eight a day, night sweats, vaginal dryness |
| Bleeding | None; light discharge |
| Scores | PHQ-9 7; GAD-7 6; pelvic pain 1 of 10 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; night sweats; no fever |
| Gastrointestinal | Negative | Bowels back to normal; no rectal bleeding |
| Genitourinary | Positive | Vaginal dryness and light discharge; no bleeding; no urinary symptoms |
| Endocrine | Positive | Hot flashes about eight a day |
| Neurological | Negative | No numbness, tingling, or ringing in the ears |
| Psychiatric | Negative | Tired but hopeful; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy | One tablet by mouth once daily | Oral route | 1951-02-09 to 1951-08-17 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day | One or two tablets every 6 hours when needed, no more than 6 a day | Oral route | 1951-02-09 | active | S |
| Nitrofurantoin (monohydrate and macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule twice daily with food for 5 days | Oral route | 1951-03-27 to 1951-03-31 | completed | S |
| Cisplatin 40 mg/m2 (64 mg) intravenous infusion once weekly for five weeks during pelvic radiation, with hydration and antiemetic premedication in the infusion center | 64 mg intravenously once weekly for five doses | Intravenous route | 1951-03-09 to 1951-04-06 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours when needed for nausea in the days after cisplatin | One tablet every 8 hours when needed for nausea | Oral route | 1951-03-09 to 1951-04-10 | completed | S |
| Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than 8 a day | Two capsules after the first loose stool, then one after each, no more than 8 a day | Oral route | 1951-03-09 to 1951-05-04 | completed | S |
| Estradiol 0.1 mg per day transdermal patch, one patch changed twice weekly | One patch changed twice weekly | Topical route | 1951-05-18 | active | S |
| Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiol | One capsule by mouth nightly | Oral route | 1951-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1951-05-18 | Body height | 165 | cm | S |
| 1951-05-18 | Body weight | 50.6 | kg | S |
| 1951-05-18 | Body mass index (BMI) [Ratio] | 18.6 | kg/m2 | S |
| 1951-05-18 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1951-05-18 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1951-05-18 | Heart rate | 80 | /min | S |
| 1951-05-18 | Respiratory rate | 14 | /min | S |
| 1951-05-18 | Body temperature | 36.6 | Cel | S |
| 1951-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1951-05-18 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 11.6-15 g/dL | Low | S |
| 1951-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 1951-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1946)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1951-05-18 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S | ||
| 1951-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1951-05-18 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 1951-05-18 | Follitropin [Units/volume] in Serum or Plasma | 72 | m[IU]/mL | Typical premenopausal follicular-phase range | High | S |
| 1951-05-18 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 14 | pg/mL | Typical premenopausal range | Low | S |
| 1951-05-18 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
Vital signs recorded on 1951-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin and tired; weight 50.6 kg; blood pressure 104/66 |
| Abdomen | Soft and non-tender |
| Skin | Mild darkening of the skin in the radiation field; no breakdown |
| Pelvic | Gentle speculum examination: radiation changes of the upper vagina; cervix smaller, without bleeding; no mass seen |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding after intercourse and between periods, with heavier periods, for about four months, with tiredness and a dull pelvic ache. Never had cervical screening. Speculum examination shows a friable, exophytic mass about 4 cm across on the cervix that bleeds on contact. Punch biopsy, HPV test and cytology taken; urgent gynecologic oncology consultation booked | resolved | confirmed | N93.8 | S — Synthetic presenting problem linked to her documented abnormal bleeding with anemia; superseded by the diagnosis at the consultation. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 9.4 g/dL, mean cell volume 72 fL, ferritin 6 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding linked to her documented anemia from vaginal bleeding. |
| Invasive squamous cell carcinoma of the cervix, HPV 16 positive: an exophytic tumor about 4.5 cm across with clinical involvement of the left parametrium, not reaching the pelvic wall; pelvic MRI and PET-CT ordered for FIGO 1943 staging. Synthetic modern episode linked to her documented cervical cancer | active | confirmed | C53.9 | S — Synthetic modern diagnosis made at the gynecologic oncology consultation. |
| Acute cystitis during pelvic chemoradiation: two days of new burning, urgency and cloudy urine on top of mild radiation frequency, without fever or flank pain; urine dipstick positive for leukocyte esterase and nitrite; culture grew Escherichia coli sensitive to nitrofurantoin; neutrophil count and kidney function normal; resolved | resolved | confirmed | N30.00 | S — Synthetic acute infection; not a historical claim. |
| Ovarian failure after pelvic radiation, with hot flashes, night sweats, poor sleep and vaginal dryness two weeks after treatment; FSH 72 mIU/mL and estradiol 14 pg/mL | active | confirmed | E89.41 | S — Synthetic expected effect of pelvic chemoradiation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Treatment side effects (bowel, bladder, skin, nausea, hearing, nerve symptoms) | Weekly during treatment, then at each visit | Completed today | Diarrhea and nausea resolved; skin intact; no hearing loss or neuropathy |
| Laboratory | Kidney function (creatinine, eGFR) and magnesium for cisplatin | Before cisplatin, weekly during it, and after | Completed today | Creatinine 0.8 mg/dL, eGFR 101, magnesium 1.9 mg/dL |
| Laboratory | Blood count (hemoglobin, white cells, platelets) | About one month after starting oral iron, then every three months for a year; weekly during chemoradiation | Completed today | Hemoglobin 11.2 g/dL |
| Laboratory | Ovarian function (FSH, estradiol) | When menopause symptoms appear after pelvic radiation | Completed today | FSH 72 mIU/mL, estradiol 14 pg/mL: ovarian failure |
| Examination | Pelvic, speculum and rectovaginal examination | At diagnosis; every three to six months for two years after treatment | Completed today | Gentle speculum examination: cervix smaller; no mass seen |
| Imaging | FDG PET-CT | At staging; about three months after chemoradiation | Due | About three months after treatment |
| Survey | Pelvic pain score and analgesic safety (no anti-inflammatory painkillers with cisplatin) | Every visit | Completed today | 1 of 10 |
| Survey | PHQ-9 and GAD-7 | At diagnosis, before treatment, at mid-treatment, at the end of treatment, and in follow-up | Deferred | PHQ-9 7 and GAD-7 6 today. The mid-treatment measures were not done: the only visit here during treatment was the sick visit for cystitis, and the weekly oncology reviews did not record them. No harm resulted: scores fell from diagnosis to today, and the social worker saw her weekly. Corrective action: the social worker now records the PHQ-9 and GAD-7 at the mid-treatment review |
| Self-management | Vaginal dilator use | Starting two to four weeks after radiation, three times a week | Completed today | Taught today; three times a week |
| Medication safety | Hormone therapy safety (blood pressure, clot symptoms) and symptom control | At the start and every visit | Completed today | Blood pressure 104/66; no clot history; starts today |
| Referral | Survivorship care plan and gynecologic oncology follow-up | From the end of treatment | Completed today | Gynecologic oncology every three months for two years |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027); Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update (2018); Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026)
Follow-up: Gynecologic oncology review in one month. PET-CT and review here about three months after treatment. Next scheduled visit 1951-08-17: review three months after treatment: PET-CT response, examination, anemia, mood, and the follow-up plan. [S]